A number of studies have shown that the expression of PD-L1 in some NSCLC patients was low or even negative, yet the response to anti-PD-1/PD-L1 was better than the response of other patients in which high expression of the same biomarker was observed [37,38,39]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.